Role of ERCC5 promoter polymorphisms in response to platinum-based chemotherapy in patients with advanced non-small-cell lung cancer

Anti-Cancer Drugs

Volumn 24, Issue 3, 2013, Pages 300-305

  He, Caiyun ^a   Duan, Zhipeng ^a   Li, Ping ^a   Xu, Qian ^a   Yuan, Yuan ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

chemotherapy; ERCC5 XPG; non small cell lung cancer; polymorphism

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ESTERASE; ETOPOSIDE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 5; GEMCITABINE; NAVELBINE; PACLITAXEL; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION INITIATION SITE; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CISPLATIN; CONFIDENCE INTERVALS; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PLATINUM; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; TRANSCRIPTION FACTORS; TRANSCRIPTION INITIATION SITE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84873405671     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32835bd6ce     Document Type: Article

References (23)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics 2008. CA Cancer J Clin 2008; 58:71-96
2. Spiro SG, Silvestri GA. The treatment of advanced non-small cell lung cancer. Curr Opin Pulm Med 2005; 11:287-291
3. Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: The role of DNA repair pathways. Clin Cancer Res 2008; 14:1291-1295
4. Rosell R, Taron M, Barnadas A, Scagliotti G, Sarries C, Roig B. Nucleotide excision repair pathways involved in cisplatin resistance in non-small-cell lung cancer. Cancer Control 2003; 10:297-305
5. Mu D, Hsu DS, Sancar A. Reaction mechanism of human DNA repair excision nuclease. J Biol Chem 1996; 271:8285-8294
6. Sabatino MA, Marabese M, Ganzinelli M, Caiola E, Geroni C, Broggini M. Down-regulation of the nucleotide excision repair gene XPG as a new mechanism of drug resistance in human and murine cancer cells. Mol Cancer 2010; 9:259
7. Sun X, Li F, Sun N, Shukui Q, Baoan C, Jifeng F, et al. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients. Lung Cancer 2009; 65:230-236
8. Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, Gibbs RA, et al. A second generation human haplotype map of over 3.1 million SNPs. Nature 2007; 449:851-861
9. Zhu LB, Xu Q, Hong CY, Yue Z, Zhang Y, Ye HN, et al. XPC gene intron 11 C/A polymorphism is a predictive biomarker for the sensitivity to NP chemotherapy in patients with non-small cell lung cancer. Anticancer Drugs 2010; 21:669-673
10. Miller AB, Hoogstraten B, Staquet M,Winkler A. Reporting results of cancer treatment. Cancer 1981; 47:207-214
11. Feng J, Sun X, Sun N, Qin S, Li F, Cheng H, et al. XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer. Acta Biochim Biophys Sin (Shanghai) 2009; 41:429-435
12. Butkiewicz D, Rusin M, Sikora B, Lach A, Chorazy M. An association between DNA repair gene polymorphisms and survival in patients with resected non-small cell lung cancer. Mol Biol Rep 2011; 38:5231-5241
13. Fagbemi AF, Orelli B, Scharer OD. Regulation of endonuclease activity in human nucleotide excision repair. DNA Repair (Amst) 2011; 10:722-729
14. Saldivar JS, Wu X, Follen M, Gershenson D. Nucleotide excision repair pathway review I: Implications in ovarian cancer and platinum sensitivity. Gynecol Oncol 2007;S56-S71
15. Chen J, Xie F, Chen K, Wang D, Jiang H, Li J, et al. ERCC5 promoter polymorphisms at -763 and + 25 predict the response to oxaliplatin-based chemotherapy in patients with advanced colorectal cancer. Cancer Biol Ther 2009; 8:1424-1430
16. Crawford EL, Blomquist T, Mullins DN, Yoon Y, Hernandez DR, Al-Bagdhadi M, et al. CEBPG regulates ERCC5/XPG expression in human bronchial epithelial cells and this regulation is modified by E2F1/YY1 interactions. Carcinogenesis 2007; 28:2552-2559
17. Mullins DN, Crawford EL, Khuder SA, Hernandez DA, Yoon Y, Willey JC. CEBPG transcription factor correlates with antioxidant and DNA repair genes in normal bronchial epithelial cells but not in individuals with bronchogenic carcinoma. BMC Cancer 2005; 5:141
18. Chen JF. Detection and functional analysis of SNPs in the ERCC5 promoter in patients with advanced colorectal cancer treated with platinum-based chemotherapy . Chongqing: Third Military Medical University; 2009
19. Gazdar AF, Thun MJ. Lung cancer, smoke exposure, and sex. J Clin Oncol 2007; 25:469-471
20. Devesa SS, Bray F, Vizcaino AP, Parkin DM. International lung cancer trends by histologic type: Male : Female differences diminishing and adenocarcinoma rates rising. Int J Cancer 2005; 117:294-299
21. Jedrychowski W, Becher H, Wahrendorf J, Basa-Cierpialek Z, Gomola K. Effect of tobacco smoking on various histological types of lung cancer. J Cancer Res Clin Oncol 1992; 118:276-282
22. Chen X, Gorlov IP, Merriman KW, Weng SF, Foy M, Keener G, et al. Association of smoking with tumor size at diagnosis in non-small cell lung cancer. Lung Cancer 2011; 74:378-383
23. Pierceall WE, Olaussen KA, Rousseau V, Brambilla E, Sprott KM, Andre F, et al. Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: Theranostic modeling by NSCLC constituent histological subclasses. Ann Oncol 2012; 23:2245-2252